GENE ONLINE|News &
Opinion
Blog

Feature
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
Bioplus Interphex 2021: CDMOs- The Manufacturing Hub for the Next Generation of Therapeutics
2021-11-30
Novel RAGE Antagonist Stirs Hopes for Countering Diabetic Complications
2021-12-07
Coherent Biopharma, WuXi STA Collab Takes a Crack at Peptide-Drug Conjugates
Antibody-drug conjugates (ADCs) dominate the spotlight for targeted cancer therapies, but are limited by poor tumor penetration as antibodies are pretty big (~150 kDa) by molecular standards. Moreover, they’re expensive to produce and carry additional risks such as stimulating undesirable immune responses and toxicity. In recent years, peptide-drug conjugates (PDC) have gained increasing attention as the next big thing in targeted therapy due to their smaller sizes, favorable safety profile and superior ability to diffuse into malignant tissue. 
2021-12-06
AstraZeneca Blocks Private Equity Buyout of Swedish Pharma Sobi
2021-12-06
Special
Bioplus Interphex 2021: CDMOs- The Manufacturing Hub for the Next Generation of Therapeutics
The Covid-19 pandemic ushered in an unprecedented era of collaboration between startups and CDMOs to bring mRNA and protein vaccines to the market at breakneck speed. At the Bioplus Interphex 2021, a global bio-pharmaceutical convention, industry leaders exchanged notes on how CDMOs can facilitate the next generation of therapeutics. In a session titled “Bio CMOs Big Leap- Pharmaceutical Optimization Production Strategy”, moderated by Young Wan Lee, Senior staff writer, Business & Technology desk, The Chosunilbo, panellists shared their views on emerging trends and the future of CDMOs. The panel consisted of:  Jinhan Shim, Senior Director, Korea Branch Office, Frost & Sullivan Jong Wook Chang, CEO, ENCell Co., Ltd. / Professor, Samsung Medical Center Seung Sin Yoo,  Head/CTO, R&D, Helixmith Co. Ltd. Jeongmin Hwang, Head of Division, Bio Production Division, Binex
2021-11-30
Cancer Cells Build Nano-Highways to Hijack Mitochondria from Immune Cells
Cancer cells escape identification and neutralization by the immune system by multiple strategies. One of them is ligand-mediated deactivation of immune checkpoints, which spurred the advent of cancer immunotherapy with anti-PD1.

However, not all patients respond well to immunotherapy, suggesting other immune evasion pathways in cancers. Researchers from MIT and Brigham and Women’s Hospital employed nanotechnology to unravel a novel mechanism of cancer cells to attack and suppress immune cells.

Co-culture of breast cancer cells with effector T cells and subsequent high-resolution imaging showed a physical linkage between cancer cells and nearby T cells with an average width of 100-1000nm. These nanotubes were composed of actin and other cytoskeletal proteins, suggesting that they may be involved in intercellular transport.
2021-11-25
Breakthrough Cryo-EM Study Reveals How Viral RNA Hijacks Host Machinery
Viruses clearly rely on the host biomachinery for their essential viral processes. Their functional versatility lies in their ability to acquire complex, multifunctional, three-dimensional, structured RNAs to molecularly hijack host proteins. However, their mechanisms can be obscured by the difficulty of solving conformationally dynamic RNA structures. Hence, designing effective strategies to uncover the novel structure-function rules of viral RNAs and their close interactions with host machinery has gained much attention recently.

In a breakthrough study published recently in Science, researchers from the University of Colorado Anschutz Medical campus have revealed how viral RNAs use a combination of static and dynamic RNA structures to bind host machinery through highly noncanonical interactions.

Using cryogenic electron microscopy (cryo-EM), the investigators have visualized the structure of the mysterious viral transfer RNA (tRNA)-like structure (TLS) from the brome mosaic virus (BMV), which affects essential viral processes, including viral replication, translation, and genome encapsidation.
2021-11-24
LATEST
Novel RAGE Antagonist Stirs Hopes for Countering Diabetic Complications
2021-12-07
AstraZeneca Blocks Private Equity Buyout of Swedish Pharma Sobi
2021-12-06
Coherent Biopharma, WuXi STA Collab Takes a Crack at Peptide-Drug Conjugates
2021-12-06
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
2021-12-03
Novartis, UCB Take Aim at Parkinson’s Disease Under $1.65 Billion Collab
2021-12-03
Atara Biotherapeutics’ First-In-Class Allogeneic T-Cell Therapy Accepted for EMA Review
2021-12-02
Deals
Ablaze Pharma Launches with $75 Million to Bring Targeted Radiotherapies into China
2021-12-01
Taiwan’s Acepodia Closes $100 Million Series C to Accelerate Cancer Assets
2021-11-22
Chroma Medicine Debuts with High Hopes for “Game-Changing” Epigenetic Genome Editors
2021-11-17
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
2021-12-03
Shanghai Startup Poised for $325M IPO on Nasdaq
2021-10-21
Oxford Nanopore Soars on London Market Debut
2021-10-05
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
Roche Gets Shareholders Nod to Repurchase $21B Equity Stake Held By Novartis
2021-11-27
Following Two Years of Promising RNAi Collab, Novo Nordisk Decides to Acquire Dicerna for $3.3 Billion
2021-11-18
Ranking & Reports
9 Leading Molecular Diagnostics Companies to Watch in Taiwan
2021-11-15
The 8 Companies Propelling Taiwan’s Biopharma Industry
2021-10-21
Taiwan’s Biotech Industry, Lackluster or Late Bloomer? A Breakdown of Policies, Hotspots, and Market Movements
2021-10-05
Categories
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
Can Regulations Measure up to the Progress of Precision Medicine in Taiwan? – An Interview With Dr. Johnsee Lee
2021-10-30
How Can Taiwan’s Biopharma Seize the Next Global Business Opportunity? – An Interview with Dr. Jerome Shen
2021-10-17
Astellas Taps Dyno in $1.6+ Billion Deal to Develop AAV Gene Therapies
2021-12-02
Experts Discuss What’s Next for Healthcare Innovation and Investment at ASGH
2021-12-02
Bioplus Interphex 2021: CDMOs- The Manufacturing Hub for the Next Generation of Therapeutics
2021-11-30
Brukinsa Receives EU Approval for the Treatment of Rare Lymphoma
2021-11-27
Starpharma Announces Encouraging Interim Results for Prostate Cancer Drug
2021-11-27
FDA Places Clinical Hold on Kura Oncology’s Acute Myeloid Leukemia Therapeutic
2021-11-25
Coherent Biopharma, WuXi STA Collab Takes a Crack at Peptide-Drug Conjugates
2021-12-06
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
2021-12-03
Ablaze Pharma Launches with $75 Million to Bring Targeted Radiotherapies into China
2021-12-01
What are Investors Looking for in a Biotech Startup?
2021-07-27
Primed to Surpass CRISPR: Prime Medicine Emerges Out of Stealth with $315 Million in Funding
2021-07-15
Blackstone Pumps $250 Million in CAR-T Startup, Betting on Intellia’s and Cellex’s Technologies
2021-06-23
Coherent Biopharma, WuXi STA Collab Takes a Crack at Peptide-Drug Conjugates
2021-12-06
10x Genomics Eyes Regional Opportunities in Asia-Pacific, Launches First Overseas Manufacturing Hub
2021-10-26
Canada Signs Deal with Moderna to Build Vaccine Plant in the Country
2021-08-12
In a Blockbuster Day, Vaccibody Gets New Name and a Multi-Program Regeneron Deal to Boot
2021-11-24
Sanofi Bets on Baidu’s Algorithm to Develop mRNA-Based Therapeutics
2021-11-23
HitGen Ink Deal with Cambridge Molecular to Create a Deep Learning-Driven Drug Discovery Platform
2021-11-08
Harnessing the potential of CRISPR-Cas9 for Gut Microbiome Gene Editing
2021-11-29
HPV Vaccination Cuts Cervical Cancer Cases by Nearly 90%: Study
2021-11-05
Could This Anti-Sperm Immunocontraception Work As a Novel Female Birth Control?
2021-08-24
Novel RAGE Antagonist Stirs Hopes for Countering Diabetic Complications
2021-12-07
CYTENA Bioprocess Solutions Closes $5M Funding to Develop Automatic High-throughput Screening Platform for Pharmaceuticals
2021-10-05 Partner
Taiwan’s AMS BioteQ Develops a New Antimicrobial Dressing Which Accelerates Diabetes Wound Healing
2021-09-22 Partner
EVENT
2021-12-13
63rd ASH ANNUAL MEETING AND EXPOSITION
Georgia, USA
2021-12-28
BIOHK2021
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!